^
Association details:
| Biomarker: | ALK T1151M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ensacove (ensartinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Excerpt:
Patients were aged 18 years or older, had stage IIIb or stage IV ALK-positive NSCLC that had progressed while they were on crizotinib therapy...Tumours with the secondary resistance mutations F1174L/V (objective response in five [71%] of seven patients with this mutation), G1269A (four [67%] of six), C1156Y (five [71%] of seven), and T1151 (two [67%] of three) were especially sensitive to ensartinib...Table 4: Efficacy of ensartinib by ALK mutation type...
DOI:
10.1016/S2213-2600(19)30252-8
Trial ID:
